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Levonorgestrel (LNg) is known for its marked progestational/contraceptive activity. As shown
in animal experiments, however, high doses ofLNg are required to elicit an androgenic response;
in contrast, considerably lower doses of LNg are required for antiovulatory (contraceptive)
action. Thus, a large dose separation exists between androgenic and contraceptive activity. When
LNg is combined with an estrogen, as in the contraceptive formulations, the androgenic response
is attenuated or negated.
The results of recent clinical trials have demonstrated that the androgenic activity of LNg is
not expressed at contraceptive doses, particularly when LNg is combined with ethinyl estradiol
(EE), as in the low-dose monophasic/triphasic formulations (monophasic [Nordette®]: 150 mcg
LNg/30 mcg EE; triphasic [Triphasil®/Trinordiolg]: six days, 50 mcg LNg/30 mcg EE; five
days, 75 mcg LNg/40 mcg EE; ten days, 125 mcg LNg/30 mcg EE). Clinical evidence from
several trials confirms that sex hormone-binding globulin levels are increased, plasma androgen
levels are decreased, and acne is markedly improved with the use ofTriphasil® and Nordette®,
suggesting a non-androgenic profile.
INTRODUCTION
The 19-nortestosterone derivatives have more than one biological activity: e.g.,
progestational, anti-estrogenic, androgenic, anabolic. The merits of a 19-nortestos-
terone steroid as a contraceptive component are judged on its ovulation-inhibiting
properties and progestational activity, and the margin of separation from other
biological activities. Initially, the steroid is profiled in animal tests using a large dose
range. When these steroids are combined with estrogen and used at contraceptive doses
in humans, however, other steroid activities may not be manifested.
As an example, levonorgestrel (LNg) has been shown in animal experiments to have
marked progestational and anti-ovulatory activity at low doses; however, in contrast,
very high doses are required to evoke an androgenic response. In animals, when low
doses of LNg are used in combination with estrogen at contraceptive doses, the
androgenic activity of LNg is not manifested; in humans, a growing body of clinical
evidence demonstrates a non-androgenic profile, substantiating the preclinical obser-
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vations. In light of these data, the androgenic property of LNg has little clinical
relevance when used at contraceptive doses in combination with ethinyl estradiol (EE).
The results reported from preclinical and clinical studies support this statement.
This paper is divided into two parts; Part I reports the preclinical demonstration in
animals of the dose separation of anti-ovulatory and androgenic activities; Part II
reports the preliminary clinical data from three studies on the effects of Triphasil® on
acne, on sex hormone binding globulin (SHBG), and on plasma androgen levels.
PART I PRECLINICAL EVIDENCE: CONTRACEPTIVE
(ANTI-OVULATORY) AND ANDROGENIC ACTIVITY
OF LEVONORGESTREL IN ANIMALS
Inhibition ofSpontaneous Ovulation in the Rat
Introduction Administration of progesterone and synthetic progestogens such
as levonorgestrel, on diestrus ofthe four-day rat estrous cycle, can prevent theexpected
occurrence ofovulation [1]. This activity appears to occur via a mechanism involving
the hypothalamic-pituitary axis, resulting in suppression ofthe ovulatory gonadotropin
surge rather than through a direct action on the ovary.
Methods Adult female Sprague Dawley CD® rats (Charles River), weighing
200-250 g, maintained under controlled lighting conditions (lights on 0500 hours-
1900 hours) and exhibiting at least two consecutive four-day estrous cycles, were
administered various doses of levonorgestrel as a single subcutaneous (sc) injection at
1330 hours on diestrus. At the subsequent estrus, two days following treatment, the
rats were sacrified by CO2 asphyxiation, and the oviducts were excised and examined
for ova under a dissecting microscope. The presence of a single ovum represents the
criterion for ovulation.
Results and Discussion Levonorgestrel blocked ovulation in a dose-dependent
fashion when administered on diestrus to the four-day cycling rat; the estimated 100
percent anti-ovulatory dose is 50-100 ,g/rat (Table 1).
Androgenic/Anabolic (Myotrophic) Effects
Introduction Certain synthetic progestogens, because of their common struc-
tural origin as derivatives of 19-nortestosterone and their similarities to this steroid and
testosterone, may possess a varying degree of androgenic and/or anabolic activity.
TABLE I
Inhibition of Ovulation by Levonorgestrel in Rats When Administered on Diestrus
Dose No. x No. Ova Shed by
Treatment (,tg/rat, sc) Ovulating/Total (% Inhibition) Ovulating Rat
Oil 14/15 (7) 14.5
Levonorgestrel 10 5/5 (0) 13.2
20 3/5 (40) 13.3
50 2/10 (80) 11.0
100 0/5 (100) 0.0
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FIG. 1. Androgenic/anabolic evaluation oflevonorgestrel in the immature castrated male rat.
Classical assays are used to evaluate such properties [2] and these tests were used to
redefine LNg's properties.
Methods Immature male Sprague Dawley CD® rats (Charles River) were
bilaterally castrated on day 27 ofage. Treatment (subcutaneous) with various doses of
LNg or the androgenic reference compound, testosterone propionate (TP), was begun
24 or 48 hours after surgery and continued for seven days. Groups of intact, untreated
rats and castrate, vehicle-treated rats served as controls. The day following the final
treatment, all rats were sacrificed by CO2 asphyxiation. The ventral prostrate and
seminal vesicles (minus contained fluid and the coagulating gland), both androgenic
targets, and levator ani (anabolic target) were removed and the weights were
recorded.
Results and Discussion Subcutaneous administration of LNg produced a
dose-dependent increase in the weights ofthe ventral prostate and seminal vesicle that
generally paralleled, but that was considerably less than, the response to testosterone
propionate (Fig. 1). Notably, the highest doses of LNg tested, 1,000-3,000 gg, did not
increase weights ofthese end organs to the extent observed with much lower daily doses
of TP (50-100 ,ug). The response of the levator ani indicates that LNg resembles
testosterone more closely in terms of anabolic effects than in terms of androgenic
activity. The dose separation of anti-ovulatory (contraceptive) activity from the
androgenic activity in rats is exemplified in the composite Fig. 2 (data derived from
Table I and Fig. 1). LNg inhibits ovulation at single low doses (estimated ED'O° = 50-
100 ,ug/rat, sc) and stimulated weight increases ofventral prostate (androgenic target
tissue) and seminal vesicles (anabolic target tissue) at much higher total doses
(700-21,000,ug/rat, sc).
Conclusionfrom the Preclinical Studies
The anti-ovulatory activity of LNg occurs with doses considerably below those
required to produce androgenic and anabolic responses from appropriate target
tissues.
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FIG. 2. The dose separation between anti-ovulatory activity and androgenic activity.
PART II CLINICAL EVIDENCE: THE EFFECTS OF LOW DOSE LNg
ORAL CONTRACEPTIVES (OCs) ON ANDROGENS AND ACNE
Introduction
A prevailing concept has been that a patient who has acne should not use a
contraceptive product containing a progestational agent with androgenic properties
[3,4]. This idea, however, is a generalization based on an extension of animal data to
humans and is not valid at the LNg doses used in combination with estrogen in the
low-dose oral contraceptives.
Because acne is a known clinical side effect of elevated androgens, it was assumed
that LNg-containing contraceptive products would exacerbate a pre-existing acne
condition because LNg has androgenic properties, albeit at high doses in animals.
In contrast, clinical evidence has been accumulating that indicates the reverse is
true: LNg at contraceptive doses in combination with EE consequently alleviates acne
in most women, which suggests a non-androgenic profile.
During clinical trials with a low-dose LNg triphasic contraceptive (Triphasil®,
Wyeth-Ayerst, Philadelphia, Pennsylvania), acne disappeared or was alleviated within
three to six months in most women who had this skin problem at study entry.
The results ofthe study by Loudon and Biddell [5] in 271 women with acne showed
that the condition disappeared or was improved within three to six months in 76
percent of the women who took the triphasic contraceptive. Other trials with the LNg
triphasic OC have further supported these original observations [6-13]. Studies in
women with acne who were taking the low-dose monophasic LNg product (Nordette®,
Wyeth-Ayerst, Philadelphia, Pennsylvania) showed 24 percent to 35 percent improve-
ment in acne within six months [14,15].
Cunliffe et al.' conducted a pilot study using the triphasic LNg product in women
with acne. The results showed that sebum production was decreased by 20 percent and
the mean grade of acne improved in all 20 patients studied during the three months of
treatment. Because the reduced sebum production was not dramatic enough to account
totally for the marked improvement in acne, another explanation was sought.
'Cunliffe WJ: A Study of the Effects ofTrinordiol on the Sebum Excretion Rate in Woman with Acne.
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Although some authors have not observed abnormal increases in plasma androgen
levels in women with acne vulgaris [16,17], the majority of studies have provided
evidence for elevated plasma androgen levels [18-22].
Some combination OCs can reduce androgen levels (e.g., total testosterone, andro-
stenedione, dehydroepiandrosterone sulfate [DHEA-S]) [6-9,14]. It was speculated
that, in women with acne, the combination contraceptives reduce androgens partly by
raising sex hormone binding globulin (SHBG) and consequently reducing circulating
free androgens, resulting in the improvement ofacne. Consequently, multi-center and
individual trials were designed to examine the effects of the triphasic preparation on
acne grade and on peripheral androgen levels in non-hirsute women as well as on
SHBG levels. Preliminary data are reported here from three separate studies.
Methods and Materials
Study No. I Dr. Cunliffe2 conducted a comparative and investigator-blinded
parallel study in which 60 patients were randomly assigned to the LNg triphasic
(Triphasil®/Trinordiol®),3 or to Diane®4 (a therapy for acne as well as a contracep-
tive). The two drugs were taken for 21 days, followed by a seven-day tablet-free
interval, and this regimen was maintained for six months. Baseline measurements were
taken at the initial assessment visit. Efficacy, safety, and patient assessments were
made after two, four, and six months. Efficacy assessments included counting the
number of non-inflamed lesions, papules and pustules, macules, and a total acne
count.
Only preliminary data on the Triphasil® (also known as Trinordiol®) patients
completed at this time are reported here. The full trial results will be the subject of a
separate publication.
Study No. 2 Drs. Aschner and Sabogals conducted a comparative parallel trial
in 20 patients that was part ofa large multi-center, multinational study. Women were
between 15 and 35 years of age and met the usual inclusions/exclusions for oral
contraceptives. In addition, women had to express the desire for contraception and
have mild to moderate acne without hirsutism. Women were randomized to either
Triphasil® or Diane®. The drugs were taken on a 21-day-on, seven-day-off regimen for
six months. Baseline measurements of acne, hormones, and SHBG were obtained at
the initial visit and repeated at follow-up visits at one, two, three and six cycles and one
month post-treatment. Clinical assessments included a physical/gynecological
examination, pretreatment; routine general laboratory chemistries; hormone tests
(androgens and luteal phase progesterone), sex hormone binding globulin; and acne
assessment at each visit. Androgen tests included total and free testosterone,
dehydroepiandrosterone sulfate (DHEA-S), and androstenedione. Assays were per-
formed using standard radioimmunoassay (RIA) methods.
Study No. 3 Dr. Lemay and colleagues [23] conducted an open, non-compara-
2Cunliffe WJ: The Effect ofTrinordiol®, Diane® or tetracycline on Acne in Healthy Young Women. Data
on File, Wyeth-Ayerst, 1989
3Triphasil®/Trinordiol®; 0.050 mg LNg and 0.030 mg EE x 6 days, 0.075 mg LNg and 0.040 mg EE x 5
days, 0.125 mg LNg and 0.030 mg EE x 10 days. Philadelphia, PA, Wyeth-Ayerst
4Diane® 2 mg cyproterone acetate and 0.050 mg ethinyl estradiol x 21 days/months. Berlin, West
Germany, Schering AG
5Aschner P, Sabogal M: The effects ofTrinordiols and Diane® in young women with acne. Data on File,
Wyeth-Ayerst, 1989
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tive trial in 40 patients to determine the effect of Triphasil®6 on acne as measured by
both subjective and objective measurements as well as the efficacy of Triphasil® as a
contraceptive.
The usual inclusion/exclusion criteria for OC use applied. In addition to physical
and gynecologic examinations, baseline measurements were taken for clinical chemis-
tries and hormone levels for androgens and progesterone, and SHBG.
Acne was graded by count and severity and categorized as comedonal or papulopus-
tular. The total count times the grade number constituted the acne severity scores. In
most instances, photographs were taken before and after six months of triphasic OC
administration. The same, most severely affected side of the face was photographed
each time.
Acne was counted on the face, anterior chest, and back. Because a contraceptive was
being used, only women with a pretreatment ovulatory cycle as judged by increase in
luteal phase progesterone were enrolled. Plasma levels of androstenedione, DHEA-S,
total testosterone, free testosterone, and SHBG were determined by RIA before
treatment, at one, two, three, and six months oftreatment. Diary cards were kept by all
patients to verify compliance, and to record any bleeding irregularities as well as any
side effects. Follow-up visits took place after cycles 1, 2, 3, and 6, at which time acne,
androgen levels, and SHBG levels were determined at each visit.
Results
Study No. I Results from the Cunliffe study2 show that most patients experi-
enced a reduction in acne; of the 13 patients reported, ten showed improvement, one
showed no change, and two became worse. Overall, a reduction of acne amounting to
56.7 percent was observed in these patients (Table 2).
Study No. 2 Preliminary results from the multi-center trial conducted in
Colombia by Aschner and Sabogal5 are reported here. Reports on the ten patients who
took Triphasil® showed that a marked reduction in the acne count was accompanied by
reductions in androgen levels (Table 2). Overall, a mean reduction of acne of 92
percent occurred in these patients. All but one of the ten patients treated showed
marked reduction in acne. In addition, SHBG increased 16 percent over pretreatment,
total testosterone (T) decreased 19 percent, free testosterone decreased 34 percent, and
DHEA-S decreased 28 percent.
Study No. 3 The preliminary results from Lemay and associates [23] (Canada)
on 34/40 patients are reported (Table 2) and the total results will be published when
studies of all patients are completed. Table 3 shows that, after three months of
treatment, androgens showed the following reductions when compared to pretreat-
ment: total T, reduction of 0.12 ng/ml (21 percent); free T, 0.5 percent (25 percent);
A, 0.9 ng/ml (33 percent); and DHEA-S, 946 ,pg/dl (32 percent); SHBG showed an
increase of 51 nmol/l (108 percent); after six months these decreases were 0.09 ng/ml
(16 percent), 0.6 percent (30 percent), 1.3 ng/ml (48 percent), 1,039 ,ug/dl (36
percent), respectively, and SHBG increased 54 nmol/l (114 percent). As one example,
Fig. 3 depicts the percentage decrease in androgen levels, acne count, and severity of
one patient, patient X, before and during treatment with Triphasil®. Figure 4 shows
photographs of patient X before and after six months of treatment with Triphasil®.
From the photographs, the improvement in facial acne is evident. The reduction in
6Triphasil formulation in Canada as used in this study contained dl-norgestrel.
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TABLE 3
Androgens* and SHBG*
Cycle T FT A DHEA-S SHBG
Normal 0.2-0.8 0.6-1.7 0.9-2.2 800-3,000
ng/ml ± SD(n) % ± SD(n) ng/ml ± SD(n) ,ug/dl ± SD(n) nmol/l ± SD(n)
Pre 0.58 ± .03 (33) 2.0 ± .06 (33) 2.7 ± 0.2 (33) 2,919 ± 212 (33) 47 ± 4.9 (33)
Cycle 1 0.44 ± .03 (32) 1.5 ± .04 (32) 1.9 ± 0.2 (32) 2,320 ± 192 (32) 96 ± 6.2 (32)
Cycle 2 0.46 ± .03 (33) 1.5 ± .04 (33) 2.0 ± 0.2 (33) 2,233 ± 194 (33) 93 ± 6.5 (31)
Cycle 3 0.46 ± .03 (32) 1.5 ± .05 (32) 1.8 ± 0.2 (32) 1,973 ± 186 (31) 98 ± 7.3 (33)
Cycle 6 0.49 ± .03 (22)** 1.4 ± .05 (22) 1.4 ± 0.1 (22) 1,880 ± 179 (26) 101 ± 9.9 (25)
*Statistically significant at 3 and 6 cycles, p < 0.01
**p < 0.05
( ) = number of patients
T, testosterone; FT, free testosterone; A, androstenedione; DHEA-S, dehydroepiandrosterone sulfate;
SHBG, sex hormone binding globulin
Reproduced from preliminary data with permission of Drs. Andre Lemay and Lucile Turcot-Lemay;
full paper in preparation
acne severity and count, pari passu with reduction in androgen levels shown in Fig. 3,
are objective evidence supporting the improvement seen in the photographs of patient
X. In this patient there was a 29 percent reduction in total T, 28 percent reduction in
free T, 12 percent reduction in androstenedione (A), 56 percent reduction in DHEA-S,
and 148 percent increase in SHBG at three months; at six months, total T had
increased 12 percent over pretreatment values, free T decreased 39 percent, DHEA-S
decreased 72 percent, and A decreased 58 percent. The observed trend in acne
improvement and androgen reduction was the same for the subsequent patients studied
in this trial.
DISCUSSION
Tables 2 and 3 list the preliminary results from these ongoing studies2'5 [23],
whereas Table 4 lists published reports on the effects oftriphasic [5-13] and low-dose
monophasic [14,15] LNg contraceptives on acne, androgen levels, and SHBG. As
indicated in compilation Table 4, both the LNg-containing triphasic and the low-dose
LNg monophasic contraceptive have been shown to raise SHBG levels significantly in
normal women and in women with acne, resulting in lower levels of free testosterone
and other plasma androgens. The present studies shown in Tables 2 and 3 corroborate
these findings and further show the simultaneous rise in SHBG, reduction in androgen
..... FREE T
100 --DHEA-S
--TOTAL FACIAL LESIONS
80
> w*** ..-SEVERITY SCORE FIG. 3. The correlation
Percent ............................. between the improvement in
Decrceas 60 total facial lesions and acne
Decrease 60 - \ \ ******--,,,,,, severity score over six
40 - months compared with the
20 _ \ ~ __ _ - decrease in androgen levels
over six months (Free T,
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0 1 2 3 4 5 6 (adapted with permission
CYCLES from [23]).
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FIG. 4. Photographs of patient X shown before treatment (A and B) and after six months of
triphasic treatment (C and D) (taken from [23] with permission).
levels, and reduction in acne. Improvement in acne was observed in all of the studies,
but the magnitude of the change differs. Patient response time also varies, but, if
improvement is to occur, it will be apparent by three to six months of treatment; these
response differences are attributed to many variables. Recent evidence has implicated
elevated plasma androgen levels in acne vulgaris. Since androgenic steroids can be
derived from the ovaries, the adrenal, and fat, including the skin (Fig. 5) [24], we must
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FIG. 5. The sources of androgen in the woman. (Adapted from [24] with permission.) GnRH,
gonadotropin-releasing hormone; CRF, corticotropin-releasing factor; FSH, follicle-stimulating hormone;
LH, luteinizing hormone; ACTH, adrenocorticotropic hormone; E,, estrone; E2, estradiol; 17 Preg,
pregnenolone; 17 Prog, 17-hydroxyprogesterone; CPDS, I I-deoxycortisol.
assume that all sources are involved in androgen production in these women. It is
known that estrogen or estrogen-dominant products raise sex hormone binding
globulin (SHBG) levels; whereas androgen dominance impedes the estrogen-induced
rise in SHBG in a dose-related manner. The higher the level of SHBG, the more
testosterone is bound and the less free testosterone is available for target tissue receptor
interaction. Consequently, since LNg OCs raise SHBG, we must conclude that the
LNg OCs are estrogen-dominant and the LNg triphasic is much more estrogen-
dominant than the low-dose LNg monophasic.
The women in these studies were not hirsute and thus the decrease in DHEA-S is
puzzling. The adrenal appears to be involved because of the changes in DHEA-S
thought to be predominantly ofadrenal origin. The levels ofpretreatment androgens in
this population, although high, are borderline normal and not suggestive ofa tumor. If
one considers the sources of androgen in the female as shown in Fig. 5 [24], one can
speculate that the skin sensitivity may also be involved. Triphasil® exerts a mild
anti-androgen effect on peripheral target tissue, i.e., the sebaceous glands of the skin
(sebum reduction).' The ovary certainly is affected by the LNg triphasic OC indirectly
and perhaps directly by effecting ovarian steroidogenesis. The women in these trials
had normal ovulatory menstrual cycles on admission to the trial, precluding disruption
of the pituitary-ovarian axis. The theory of Lucky et al. [4], which postulates
exaggerated adrenarche perhaps due to hypertrophy of the zona reticularis, is also
possible in these women. Further studies are required to define more clearly the
mechanism(s) of action of these OCs, such as effects on steroid enzyme levels. The
clinical effect of LNg low-dose OCs by whatever mechanism, however, is to raise
SHBG, reduce androgens, and improve acne.
CONCLUSIONS FROM THE CLINICAL STUDIES
Published clinical data from many sources (Table 4) show that the use of LNg
triphasic OC leads to an increase in SHBG, to a reduction in plasma androgen levels,
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and to an improvement in acne. These data lend support to the concept that LNg
monophasic and triphasic preparations do not manifest androgenic properties at the
doses and combinations (with estrogen) used in these low-dose OCs. Because an
increase in SHBG is distinctly an estrogenic response, and because both low-dose
monophasic and triphasic LNg products increase SHBG, these formulations are not
considered androgenic. The improvement observed in acne, a disorder induced and
supported by androgen, with the use of low-dose LNg monophasic/triphasic prepara-
tions, should not be interpreted as suggesting that these contraceptives are a new
therapy for acne; rather, these data suggest that LNg low-dose monophasic and
triphasic preparations are the preferred treatment for women who require contracep-
tion and who also have acne.
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